GVR Report cover Digital Respiratory Devices Market Size, Share & Trends Report

Digital Respiratory Devices Market Size, Share & Trends Analysis Report By Product (Smart Inhalers & Nebulizers, Sensors & Apps), By Indication, By Distribution Channel, By End-use, By Region, And Segment Forecasts, 2022 - 2030

  • Report ID: GVR-4-68039-968-5
  • Number of Pages: 120
  • Format: Electronic (PDF)
  • Historical Range: 2017 - 2020
  • Industry: Healthcare

Report Overview

The global digital respiratory devices market size was valued at USD 36.2 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 28.5% from 2022 to 2030. The market growth can be attributed to the significant increase in the incidence rate of severe chronic respiratory diseases (CRDs) such as bronchial asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, lung disorders, and pulmonary hypertension (PH). The likelihood of developing CRDs is progressively increasing as a result of a rise in the geriatric population, tobacco use, increased air pollution, and occupational exposure to dust in the mining, forestry, and agricultural sectors. As a result, the demand for respiratory management devices is growing at a rapid pace. The COVID-19 pandemic has made clinical testing, regulatory procedures, and post-approval activities more challenging. This is mostly a result of difficulties with patient recruitment, enrollment, and treatment in clinical studies.

U.S. digital respiratory devices market size, by product, 2020 - 2030 (USD Billion)

However, in the post-pandemic era, smart inhaler adoption is anticipated to increase as healthcare professionals turn to connected medical devices to ensure that patients receive the best care and consultation possible, regardless of the circumstance. This is because the pandemic's restrictions had an adverse effect on many patients who were unable to receive consultations and treatments in person.

The pandemic demonstrated how serious respiratory illnesses and infections may become if not treated quickly and carefully. The currently available findings suggest that digital inhalers improve medication management and direct clinical care in asthma and COPD patients, with the benefits of increased medication adherence having the capacity to boost clinical outcomes and avoid the need for expensive or more complicated therapies, such as biologics.

Additionally, a 12-month controlled study conducted in January 2017 at the Sheffield Children’s Hospital, U.K. observed positive outcomes with the use of Adherium’s smart inhaler system. The positive medical outcomes included lesser hospitalizations, enhanced adherence to medication schedules, and a reduced need for doctor visits. A rising number of significant advancements in digital respiratory technology is driving the market worldwide. For instance, FindAir medical with its CE-marked FindAir ONE smart inhaler device is publicly accessible in Europe since January 2019.

A growing number of organizations are incorporating digital technologies into their devices to improve the efficiency of medication management. For instance, Aptar Pharma launched HeroTracker Sense in April 2022. It’s a new digital respiratory health solution that converts a typically metered dose inhaler (pMDI) into a smart connected healthcare device.

In addition, asthma, a significant non-communicable illness that affects both children and adults, is predicted to have impacted 262 million people globally in 2019. Chronic obstructive pulmonary disease (COPD) was responsible for about 3.23 million deaths in the same year. Moreover, approximately 300 million people globally are now suffering from asthma, and the prevalence of the condition is increasing by 50% every ten years. Moreover, over 200 million people worldwide suffer from COPD.  In addition, slightly more than 8% of all chronic diseases in the world are respiratory diseases.

Product Insights

In 2021, the smart inhalers and nebulizers segment held the largest revenue share of over 60.0% and is expected to register the fastest CAGR during the forecast period. The growing prevalence of asthma and other respiratory conditions and the rising air pollution levels are expected to contribute to the growing demand for digital respiratory devices. Moreover, patients with asthma and COPD have been shown to adhere more frequently while using smart inhalers. In addition, when compared to conventional inhalers, smart inhalers assist more effectively and monitor the technique used for inhaling the medication. In July 2020, Novartis International AG got EC clearance for Enerzair Breezhaler. This device is the first digital companion (sensor and app), which is prescribed with medication for uncontrolled asthma in the European Union. Based on product, the market is segmented into sensors and apps and smart inhalers and nebulizers.

The sensors and apps segment is anticipated to expand at a CAGR of 27.8% over the forecast period. The adoption of respiration sensors to enable continuous and non-invasive patient monitoring is one of the key factors driving the sensors and apps market. The market is also being driven by the aging population, respiratory problems, and an increase in life expectancy.

Indication Insights

The COPD segment dominated the market with a revenue share of over 50.0% in 2021. COPD affects 200 million people worldwide.  In addition, slightly more than 8% of all chronic diseases in the world are respiratory diseases. According to the World Health Organization prediction (2020), COPD will surpass ischemic heart disease and HIV/AIDS to become the fourth-leading causes of death, respectively, by 2030. Furthermore, people continuing to smoke and longer life expectancies are all contributing to the considerable increase in COPD; these changes are particularly significant in emerging nations. Based on indication, the market is segmented into asthma, COPD, and other diseases.

The asthma segment is anticipated to expand at a CAGR of 27.4% during the forecast period. Approximately 300 million people globally are now suffering from asthma, and the prevalence of the condition is increasing by 50% every ten years. In addition, 10% of people in North America suffer from asthma and it affects over 25 million people in the U.S. Moreover, a surge in severe asthma, inadequate disease treatment, and poverty are all effects of the increasing frequency of asthma hospitalizations, especially among young children. As a result, the demand for digital respiratory devices is increasing.

Distribution Channel Insights

The hospital pharmacies segment accounted for the largest revenue share of over 35.0% in 2021. The older population is regularly hospitalized in hospitals for various chronic respiratory illnesses, and they obtain medicine from hospital pharmacies for such conditions. Additionally, hospital pharmacies give medicinal supplies to healthcare professionals so that patients may easily obtain medications. The market for hospital pharmacies is expanding as a result of the growing population and rising prevalence of chronic respiratory diseases. Based on the distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies.

The online pharmacies segment is anticipated to expand at the fastest CAGR of 31.1% over the forecast period. The market growth is being favorably impacted by the quick expansion and modernization of existing e-pharmacies to boost market penetration. Moreover, the expansion of e-prescription uses in hospitals and other healthcare facilities, an increase in online consumers, better access to web-based and online services, and other factors all contribute to the expansion of the online pharmacy industry.

End-use Insights

In 2021, hospitals accounted for the largest revenue share of over 50.0%. The market for hospitals is anticipated to grow significantly over the next few years as a result of expanding public-private partnerships, rapid improvements in healthcare infrastructure, and improved access to healthcare services. The market is segmented into hospitals, homecare settings, and other settings.

Global digital respiratory devices market share, by end-use, 2021 (%)

The homecare settings segment is anticipated to expand at the fastest CAGR of 29.5% during the forecast period due to the financial benefits of home care equipment and services compared to hospital visits. In addition, many individuals with chronic respiratory disorders prefer to get care in homecare settings as a result of the growing expense of the healthcare industry. Moreover, the growing incidence of chronic illnesses such as COPD and asthma throughout the world is the main driver of the homecare market.

Regional Insights

In 2021, North America dominated the market with a revenue share of over 45.0% owing to the rising rates of asthma, COPD, and other chronic respiratory diseases. Asthma affects more than 25 million people in the U.S. Moreover, 14.8 million adults have COPD, and annually, more than 150,000 Americans die from COPD or one death every four minutes. Furthermore, significant improvements in digital respiratory products and their growing acceptability and accuracy are expected to fuel the market growth during the forecast period. The U. S. Centers for Medicare & Medicaid Services (CMS) recently released the 2022 reimbursement rates for Current Procedural Terminology (CPT) codes for Remote Physiologic Monitoring (RPM) as well as Remote Therapeutic Monitoring (RTM) services. This amendment will increase the use of and demand for digital respiratory devices during the forecast period in the U.S.

Digital Respiratory Devices Market Trends by Region

Asia Pacific is projected to expand at a lucrative CAGR of 30.7% during the forecast period. This growth can be attributed to growing COPD and asthma incidence rates in China and India. In China, COPD positions first among the leading cause of disability and is a growing public health concern. In May 2020, Bevespi Aerosphere from AstraZeneca received approval in China as maintenance therapy for treating symptoms of COPD, which includes chronic bronchitis and/or emphysema.

Key Companies & Market Share Insights

Geographical expansions through mergers and partnerships and product launches are some of the key strategies being adopted by the market players. For instance, in September 2021, Adherium Limited, a key player in the respiratory eHealth, remote monitoring, and data management market, announced that the FDA's 510(k) approval has allowed it to begin selling its first, next-generation Hailie Sensor, which includes physiological measures for tracking the use of asthma and COPD medications.

Moreover, in November 2019, Propeller Health broadened a pharmacy refill app to include CVS, Rite-Aid, Kroger, and Walmart pharmacies. The company also introduced My Pharmacy, an in-app feature in January 2019 with Walgreens, which connects customers to manage their prescription refills for COPD and asthma to locate a nearby pharmacy. Some prominent players in the global digital respiratory devices market include:

  • COHERO Health Inc.

  • Cognita Labs

  • Adherium Limited

  • Amiko Digital Health Limited

  • Teva Pharmaceuticals Industries Ltd.

  • Propeller Health

  • Novartis AG

  • Pneuma Respiratory Inc.

  • 3M Health Care Limited

  • AireHealth, Inc.

  • FindAir Sp. z o.o

Digital Respiratory Devices Market Report Scope

Report Attribute

Details

Market size value in 2022

USD 41.0 billion

Revenue forecast in 2030

USD 304.3 billion

Growth rate

CAGR of 28.5% from 2022 to 2030

Base year for estimation

2021

Historical data

2017 - 2020

Forecast period

2022 - 2030

Quantitative units

Revenue in USD million/billion and CAGR from 2022 to 2030

Report coverage

Revenue forecast, company share, competitive landscape, growth factors & trends

Segments covered

Product, indication, distribution channel, end-use, region

Regional scope

North America; Europe; Asia Pacific; Latin America; MEA

Country scope

U.S.; Canada; U.K.; Germany; France; Italy; Spain; Japan; China; India; Brazil; Mexico; South Africa

Key Companies profiled

COHERO Health Inc.; Cognita Labs; Adherium Limited; Amiko Digital Health Limited; Teva Pharmaceuticals Industries Ltd.; Propeller Health; Novartis AG; Pneuma Respiratory Inc.; 3M Health Care Limited; AireHealth, Inc.; FindAir Sp. z o.o

Customization scope

Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional, and segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options

 

Global Digital Respiratory Devices Market Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2017 to 2030. For this study, Grand View Research has segmented the global digital respiratory devices market report based on product, indication, distribution channel, end-use, and region:

Global Digital Respiratory Devices Market Segmentation

  • Product Outlook (Revenue, USD Million, 2017 - 2030)

    • Smart Inhalers & Nebulizers

    • Sensors & Apps

  • Indication Outlook (Revenue, USD Million, 2017 - 2030)

    • Asthma

    • COPD

    • Other Diseases

  • Distribution Channel Outlook (Revenue, USD Million, 2017 - 2030)

    • Hospital Pharmacies

    • Retail Pharmacies

    • Online Pharmacies

  • End-use Outlook (Revenue, USD Million, 2017 - 2030)

    • Hospitals

    • Homecare Settings

    • Other Settings

  • Regional Outlook (Revenue, USD Billion, 2017 - 2030)

    • North America

      • U.S.

      • Canada

    • Europe

      • U.K.

      • Germany

      • France

      • Italy

      • Spain

    • Asia Pacific

      • Japan

      • China

      • India

    • Latin America

      • Brazil

      • Mexico

    • Middle East & Africa

      • South Africa

Frequently Asked Questions About This Report

gvr icn

GET A FREE SAMPLE

gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

gvr icn

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

esomar icon

ESOMAR certified & member

D&B icon

Leading SME award by D&B

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.